Coya Therapeutics Announces Publication Demonstrating Regulatory T-Cell Dysfunction and Systemic Inflammation in Frontotemporal Dementia, Supporting Mechanistic Rationale for COYA 302 Immune-Restoring Therapy

Study results demonstrate significant reduction in regulatory T cell (Treg) function and significant increase in circulating pro-inflammatory cytokines and chemokines in patients with FTD

Low-dose IL-2 plus CTLA-4 Ig has previously demonstrated restoration of regulatory T-cell function together with reduction of inflammatory cytokines and monocyte activation in treated patients

Findings of this biomarker study are consistent with previously reported results of an Investigator-Initiated-Trial of LD IL-2 and CTLA-4 Ig in patients with FTD

HOUSTON--(BUSINESS WIRE)-- Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance Treg function, announces the publication of a research study led by Dr. Alireza Faridar and Dr. Stanley Appel at the Houston Methodist Neurological Institute, demonstrating the involvement of the peripheral immune system in the neuroinflammatory profile of frontotemporal dementia (FTD). The study has been published in the peer-reviewed journal Brain Communications and can be accessed here.

Dr. Fred Grossman, Chief Medical Officer at Coya said, “We believe these biomarker data coupled with the clinical and lab results of the clinical study in FTD provide additional evidence supporting the development of biologic combination therapies that enhance the function of regulatory T cells and target inflammation in FTD, ALS and other neurodegenerative diseases of high unmet need.”

Summary of Study Results

Blood samples were obtained from 27 patients clinically diagnosed with FTD and 25 age-matched healthy individuals as a control group.

Comprehensive analyses revealed significantly lower regulatory T cell (Treg) immunomodulatory suppressive function in FTD patients compared to healthy controls (p